These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18462058)

  • 1. The strong financial case for regenerative medicine and the regen industry.
    Mason C; Dunnill P
    Regen Med; 2008 May; 3(3):351-63. PubMed ID: 18462058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
    Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
    Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introducing new contraceptives.
    Segal SJ; Coutinho E
    Draper Fund Rep; 1986 Dec; (15):27-32. PubMed ID: 12341234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
    Smart A; Martin P
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2010 Feb; (166):29-40. PubMed ID: 20377662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can Regenerative Medicine Help Close the Gap Between the Medicine Pipeline and Public Health Burden of Cardiovascular and Musculoskeletal Diseases?
    Hossain I; Milne C
    Clin Ther; 2018 Jul; 40(7):1066-1075. PubMed ID: 30029792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Public-private partnership: from there to here.
    Croft SL
    Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S9-14. PubMed ID: 16087204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early evaluation and value-based pricing of regenerative medicine technologies.
    Koerber F; Rolauffs B; Rogowski W
    Regen Med; 2013 Nov; 8(6):747-58. PubMed ID: 24147530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Private sector joins family planning effort.
    Front Lines; 1989 Dec; ():6, 13. PubMed ID: 12343476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health care cost containment strategies: the Jordanian experience.
    Rawabdeh AA
    Int J Health Plann Manage; 2005; 20(1):53-66. PubMed ID: 15799457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global strategic partnerships in regenerative medicine.
    French A; Suh JY; Suh CY; Rubin L; Barker R; Bure K; Reeve B; Brindley DA
    Trends Biotechnol; 2014 Sep; 32(9):436-40. PubMed ID: 25150363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manufacturing road map for tissue engineering and regenerative medicine technologies.
    Hunsberger J; Harrysson O; Shirwaiker R; Starly B; Wysk R; Cohen P; Allickson J; Yoo J; Atala A
    Stem Cells Transl Med; 2015 Feb; 4(2):130-5. PubMed ID: 25575525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation, manufacturing and building industry consensus.
    Deans R
    Regen Med; 2012 Nov; 7(6 Suppl):78-81. PubMed ID: 23210816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.